In the node-negative population, the designated risk groups are as follows: Recurrence score ≤11: low risk.
Chemotherapy is not indicated for this group.
Recurrence score >11 and ≤25: intermediate risk.
Chemotherapy decision-making is complex and personalized for this group.
Patient age ( ≤50 vs.
>50 years), clinicopathological features, patient preference, and more are incorporated into this decision.
Recurrence score >25: high risk.
Chemotherapy is indicated for this group.
In the postmenopausal node-positive population, the designated risk groups are as follows: Recurrence score ≤25: low risk.
Chemotherapy is not indicated for this group.